Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - ASSETS

SELECTED FINANCIAL STATEMENT - ASSETS

9 Months Ended

Sep. 30, 2022

Balance Sheet Related Disclosures [Abstract]

SELECTED FINANCIAL STATEMENT - ASSETS

NOTE 4 — SELECTED FINANCIAL STATEMENT — ASSETS

Inventories consisted of the following (in thousands):

	September 30, 2022			December 31, 2021
Raw materials and components	$	1,493		$	1,439
Work-in-process		278			115
Finished goods		5,598			6,228
Inventory reserve		(4,630	)		(3,390	)
Total inventories, net	$	2,739		$	4,392

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30, 2022		December 31, 2021
Prepaid insurance	$	134	$	660
Prepaid expenses		328		326
Other current assets		511		394
Total prepaid expenses and other current assets	$	973	$	1,380

Property and equipment consisted of the following (in thousands):

	September 30, 2022			December 31, 2021
Equipment	$	360		$	342
Leasehold improvements		39			39
Furniture and fixtures		99			103
Construction-in-progress		—			57
Total property and equipment		498			541
Less: accumulated depreciation		(420	)		(394	)
Total property and equipment, net	$	79		$	147

During the three months ended September 30, 2022 and 2021, depreciation expense was approximately $9,000 and $11,000, respectively. During the nine months ended September 30, 2022 and 2021, depreciation expense was approximately $30,000 and $34,000, respectively.